Form 4: Ovid Therapeutics Director Karen Bernstein Granted Stock Options

Ovid Therapeutics director Karen Bernstein was granted 90,000 stock options on December 12, 2024, which vest over 36 months.

Summary

• Karen Bernstein, a director at Ovid Therapeutics, was granted 90,000 stock options on December 12, 2024.
• The options have an exercise price of $1.06 per share.
• These options will vest in 36 equal monthly installments, contingent on Ms. Bernstein's continued service.
• The options expire on December 11, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate action of granting stock options to a director, which is generally viewed positively as it aligns interests. There are no negative implications.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The stock options will vest over the next 36 months, subject to the director's continued service.

Industry Context

Stock option grants are a common form of compensation for directors and executives in the biotechnology industry, aligning their interests with the company's long-term performance.

Comparison to Industry Standards

• Stock option grants are a standard practice for compensating board members in the biotech industry.
• The vesting schedule of 36 months is typical for such grants, encouraging long-term commitment.
• The exercise price of $1.06 is a common practice, often set at or near the market price at the time of the grant.

Stakeholder Impact

• The stock option grant may be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.
• The vesting schedule encourages the director's continued service and commitment to the company.

Key Dates

Keywords

stock options, Ovid Therapeutics, Karen Bernstein, director, equity compensation, vesting